Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2025-2031

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2025-2031

The global Benign Prostatic Hyperplasia (BPH) Drugs market size is predicted to grow from US$ 3478 million in 2025 to US$ 4256 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man"s life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

LP Information, Inc. (LPI) ' newest research report, the “Benign Prostatic Hyperplasia (BPH) Drugs Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Drugs sales for 2025 through 2031. With Benign Prostatic Hyperplasia (BPH) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Drugs industry.

This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

Segmentation by Application:
Hospitals
Drugstores
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Drugs market?

What factors are driving Benign Prostatic Hyperplasia (BPH) Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Benign Prostatic Hyperplasia (BPH) Drugs market opportunities vary by end market size?

How does Benign Prostatic Hyperplasia (BPH) Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.